Natalizumab for moderate to severely active Crohn's disease - horizon scanning review
NHSC
Record ID 32004000882
English
Authors' objectives:
To summarise the currently available evidence on natalizumab for moderate to severely active Crohn's disease.
Authors' recommendations:
Natalizumab (Antegren), a recombinant humanised antibody against alpha-4 (a4) intergrin, is in phase III clinical trials to reduce signs and symptoms (maintain response and remission) in patients with moderate to severely active Crohn's disease who have not responded to therapy with steroids and immunosuppressants. Natalizumab is administered at a dose of 300mg monthly by intravenous infusion. Results from phase III placebo-controlled, randomised trials have been published in abstract form and show a significant increase in response and remission at 12 weeks.
Authors' methods:
Overview
Details
Project Status:
Completed
Year Published:
2004
URL for published report:
http://www.psy-flow.com/sites/psy-flow/files/docs/flow.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Antibodies, Monoclonal
- Crohn Disease
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.